We found that patients with T2DM treated with insulin have a significantly higher risk of 5-year incident HF compared with each of the 3 alternative treatments—GLP-1 RAs, DPP-4Is, and SGLT2Is. This evidence concerns the gene GLP1R and hydrops fetalis.